Tag: M.W:200-300

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

COMPOUHD 48; 5-(4-Nonyloxy-phenyl)-10J5,20-tris-[4-(3-trimethylammonio- propyloxy)-phenyl] -porphyrin trichloride; Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)- trimethylammonium bromide (162mg, 0.62 mmol, lOeqv.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv.) is suspended under argon in absolute DMF (30 mL) and the mixture is stirred at 550C for 12 h. The solvent is removed in vacuo at 5O0C and the residue re- dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (lOOOmL). The product is eluted with acetic acid:methanol:water (3 :2:1 by vol.). The solvents are removed under reduced pressure and the product further purified by chromatography on a column (10Og) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5: 1 by vol., upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum o give a violet solid. 1H-NNZ[R: deltaH (300MHz, CD3OD): 0.89 (t, 3H, 3J= 7.5 Hz). 1.18-1.34 (m, 10H)5 1.41 (bs, 2H), 1.73 (quint 2H, 3J- 7.5 Hz), 2.30-2.44 (m, 6H), 3,31 (bs, 27H)5 3.65-3.73 (m, 6H)5 3.93 (t 2H, 3J = 7.5 Hz)5 4.25-4.42 (m, 6H), 7.08 (d, 2H5 3J= 7.5 Hz)5 7.30 (d, 6H, 3J= 7.5 Hz)5 7.93 (d, 2H5 3J= 7.5 Hz)5 8.05 (d, 6H5 3J= 7.5 Hz), 8.94 (bs, 8H)

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.,485-71-2

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,485-71-2

Resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid The resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid was carried out via reaction with the following chiral bases: BrucineQuinine(-)-Cinchonidine(+)-CinchonineR-(+)-1-Phenylethylamine(1 R,2S)-(-)-Ephedrine hydrochloride(1S,2R)-(+)-Ephedrine hydrochloride. In each case the reactions were carried out with 0.5 and 1 equivalents of base in respect to 1 equivalent of the acid compound and by using the following solvents EthanolAcetoneAcetonitrilDioxaneEthylacetateChloroform. The results are summarized in the following tables. It may be understood that the afore mentioned crystallisation experiments that are not reflected in the following tables did not yield crystals of the respective salts under the given conditions. However, suitable conditions for crystallization of these salts can be determined by those skilled in the art via routine experiments. In the following tables Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazo)e-3-carboxylic acid R-Acid represents the respective derivative of (R)-5-( 4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acidProcesses for crystallisation: Process A: A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.Process C: A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.Process D: The chiral base was directly added on top of a solution of the racemic acid at room temperature.Process E: The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.Process F: The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.Resolution with (-)-Cinchonidine [Show Image] Acid g (mmol) Eq. amine Proc. Solvent for crystallisation T CrystYield 1st Cryst. % % S-Acid % R-Acid0,4 g (1,09 mmol) 1 F 2ml dioxane r.t 31 94,4 5,60,4 g (1,09 mmol) 1 F 19ml Ethylacetate r.t 28,5 95,8 4,20,4 g (1,09 mmol) 1 F 20ml acetone r.t. 19,6 96,9 3,10,4 g (1,09 mmol) 1 F 24ml acetonitrile r.t 42 85,8 14,1

The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Laboratorios del Dr. Esteve S.A.; EP1944293; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29176-55-4, 2,9-Dichloro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Stille couplingThe rigid ligand 66 was obtained by Stille bis-coupling, by condensing two residues of tributylstannylpyridazine 39 with the 2,9-dibromo-1,10-phenanthroline 65b, with a yield of 91%, whereas its dichlorinated homolog 65a enables only a more modest yield of 62% to be obtained (Scheme 31).

29176-55-4, 29176-55-4 2,9-Dichloro-1,10-phenanthroline 355196, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.); US2010/298562; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

4,4?-Dimethoxy-2, 2?-bipyridine (188 mg, 0.87 mmol) and sodium hexafluorophosphate (146 mg, 0.87 mmol) added to a suspension of 6 (200 mg, 0.17 mmol) in chloroform (40 mL). The mixture was refluxedat 60 ¡ãC for 48 h. The solution was concentrated to approximately 2 mLunder vacuum. Ether (20 mL) was added to the solution to give a yellow precipitate. After filtration, the crude product was purified by column chromatography (alumina gel; eluted with dicloromethane/methanol, 100:1 v/v) to give a yellow solid 3 (146 mg, 69percent). 1H NMR (400 MHz,CD3CN): delta=9.7 (d, 3JPH=20 Hz, 1 H, IrCH), 7.7?8.7 (m, 6 H, bipyridyl),7.0?7.7 (m, 30 H, PPh3), 5.2?6.4 (m, 4 H, phenyl), 4.04, 4.00 (s,6H, OCH3). 31P NMR (162 MHz, CD3CN): delta=11.5 (d, J=9.2 Hz,CPPh3), – 9.9 (s, IrPPh3). 13C NMR (101 MHz, CD3CN): delta=193.7 (s,IrCH), 167.7 (d, 2JPC=23.9 Hz, COCH3), 157.6, 157.3, 153.9, 150.9 (s,bipyridyl), 152.5 (d, 2JPC=19.4 Hz, IrCHC(PPh3)C), 146.3 (d, 2JPC=19.1 Hz, IrC), 112.1?136.1 (m, PPh3, phenyl, and bipyridyl),110.7 (d, 1JPC=90.6 Hz, IrCHC(PPh3)), 54.6, 54.3 ppm (s, OCH3). HRMS:m/z [M]+ calcd for C56H47ClIrN2O2P2+ 1069.2425, found1069.2422. IR (KBr, cm?1): 840 (P?F). Anal. Calcd for C56H47ClF6IrN2O2P3: C 55.38, H 3.90, N 2.31. Found: C 55.09, H 4.11,N 2.55percent.

17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Hu, Yuxuan; Dong, Yubao; Sun, Xiaona; Zuo, Guorui; Yin, Jun; Liu, Sheng Hua; Dyes and Pigments; vol. 156; (2018); p. 260 – 266;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.

787-70-2, A mixture of Cu(NO3)2 (0.2 mmol, 58.2 mg), 1,3-bip(0.20 mmol, 35.2 mg), NaOH(0.2 mmol, 8 mg) and H2bpdc(0.20 mmol, 58.2 mg) in DMF-H2O (6 mL, V:V 1:1) binary solventwas placed in a 25 mL Telfon-lined stainless steel container, whichwas heated to 150 C for 3 days, and then cooled to room temperatureover 24 h. Yield: 65% based on copper.Elemental analysis (%): calcd for C23H26CuN4O7 (Mr 534.03): C50.27, H 3.94, N 13.8; found: C 50.36, H 3.62, N 13.81. IR(cm1):3434(bs),3134(w),2919(w),2865(w),1650(m),1589(m).1536(m),1389(m),1106(w), 838(m),765(m).

787-70-2 [1,1′-Biphenyl]-4,4′-dicarboxylic acid 13084, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Lu, Jiu-Fu; Wang, Min-Zhen; Liu, Zhi-Hong; Journal of Molecular Structure; vol. 1098; (2015); p. 41 – 46;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.148332-36-9,[2,2′:6′,2”-Terpyridine]-4′-carboxylic acid,as a common compound, the synthetic route is as follows.,148332-36-9

Take the material according to the following specific mass or volume:Htpc (27.7 mg, 0.1 mmol),CrCl3¡¤6H2O (40 mg, 0.15 mmol),DMF (12.9 mmol, 1 mL),CH3CN (1mL),H2O (9mL),HNO3 (21 uL, 7 mol/L).The above materials were placed in a 25 mL reaction kettle.Stir for 0.5 to 1.5 hours,Warming up to 120 ¡ã C,After 3 days of reaction,Naturally cooled to room temperature,Light red crystals were observed,Is the target product,Filter it out of the mother liquor,Water washing,It is naturally dry after finishing.

148332-36-9 [2,2′:6′,2”-Terpyridine]-4′-carboxylic acid 2762749, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Chongqing Normal University; Chen Xin; Zhang Ruyi; Huang Kunlin; Ding Xumeng; Guo Yuanyuan; (9 pag.)CN108997432; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5350-41-4,N,N,N-Trimethyl-1-phenylmethanaminium bromide,as a common compound, the synthetic route is as follows.

5350-41-4, [Method A (cations)] Titrationcurves were obtained in CDCl3 at 25 oC, by adding stocksolution of host 1 to a constantconcentration (2 mM) of a guest. Up-field shift of the guest cation, especiallyCH3 or CH2, was observed. Plots of the variations of thechemical shift of the guest upon addition of the titration were registered.[Method B (anions)] Similarly,titration curves were obtained in CDCl3 at 25 oC, byadding stock solution of a guest to a constant concentration (2 mM) of host 1. Since down-field shift of amideprotons of the host 1 was observed,plots of the variations of the chemical shift of the guest upon addition of thetitration were registered.[Estimation of Ka]Titration data were then treated according to a standard binding isotherm forthe case of 1:1 association.2 Non-linear curve fitting usingKaleidaGraph 4.1 (Synergy Software) software package afforded Ka and Ddmax.

5350-41-4 N,N,N-Trimethyl-1-phenylmethanaminium bromide 21449, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Akazome, Motohiro; Hamada, Norihiro; Takagi, Koji; Yagyu, Daisuke; Matsumoto, Shoji; Tetrahedron Letters; vol. 55; 14; (2014); p. 2226 – 2229;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The phase-transfer catalysts (C1-C11) were synthesized according to the proceduresbelow. To a solution of cinchonidine (1.00 g, 3.4 mmol) in THF (50 mL) was addedthe aryl benzyl bromides (3.4 mmol). The mixture was heated for 6-8 h at reflux.After cooling to room temperature, the mixture was poured into MTBE (150 mL)under stirring. The precipitated solid was filtrated and recrystallized fromCH3OH/MTBE to afford C1-C11

485-71-2, As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Li, Ruipeng; Liu, Zhenren; Chen, Liang; Pan, Jing; Zhou, Weicheng; Beilstein Journal of Organic Chemistry; vol. 14; (2018); p. 1421 – 1427;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI